Skip to content
TrialScanner

NCT02152631

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

Phase 3Active, not recruitingLLYLead

Registry record

Lead sponsor
Eli Lilly and Company
Conditions
Non Small Cell Lung Cancer
Primary completion
Sep 15, 2017Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02152631 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.